Metropolis Healthcare eyes 13-15% growth in FY27

Metropolis Healthcare Ltd management struck an optimistic tone during its post-results conference call, reiterating a strong 13-15% growth target for FY27 despite the company reporting a mixed set of Q4FY26 numbers.

The diagnostic chain’s management said it remains confident about sustaining double-digit growth momentum, supported by rising patient volumes, improving realization trends and expanding regional contribution.

Metropolis Healthcare reported consolidated Q4FY26 revenue of ₹425 crore, up 23% year-on-year from ₹345 crore in the corresponding quarter last year.

Net profit for the quarter surged 74.3% YoY to ₹51 crore compared to ₹29 crore a year earlier.

EBITDA rose sharply to ₹108 crore from ₹62 crore in Q4FY25, while EBITDA margin expanded significantly to 25.4% from 18%.

The company also recommended a final dividend of ₹1 per share.

According to management commentary during the earnings call, organic revenue growth stood at 15% year-on-year, while both patient volumes and revenue per patient increased 11% YoY.

Management highlighted that North India’s contribution to overall revenue increased to 17%, indicating continued traction in newer expansion markets beyond its core western India franchise.

The company also pointed to a sharp improvement in profitability metrics, with gross margin expanding 182 basis points year-on-year to 80.5%.

Brokerage firm Morgan Stanley maintained its “Equal-weight” rating on Metropolis Healthcare with a target price of ₹564.25 following the results and concall interaction.

The brokerage noted that despite the Q4 miss versus expectations, the company’s operational trends remain healthy, aided by strong organic growth, improving regional mix and margin expansion.

Market participants appear to be closely watching management’s confidence around sustaining 13-15% growth in FY27 amid increasing competition in the diagnostics space.

At 10:07 AM, Metropolis Healthcare shares were trading at ₹552.70 on the NSE, up 0.86% from the previous close of ₹548. The stock had touched an intraday high of ₹600 earlier in the session.

Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Views mentioned are those of the company management and brokerages.